A melanocortin receptor agonist originally derived from Melanotan II that acts centrally to enhance sexual arousal and function in both men and women.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →PT-141, known by its pharmaceutical name bremelanotide, is a cyclic heptapeptide that occupies a genuinely unusual position in the peptide research landscape. Most compounds studied for sexual dysfunction work peripherally — they dilate blood vessels, increase genital blood flow, or modulate hormones at the gonadal level. PT-141 takes a fundamentally different approach. It acts centrally, targeting specific receptors deep in the brain to directly activate the neural circuitry associated with sexual desire. That distinction matters enormously, both mechanistically and clinically.
The story of PT-141 begins with Melanotan II, a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) originally developed with skin-tanning applications in mind. Researchers at the University of Arizona noticed something unexpected during early Melanotan II trials: study participants were reporting spontaneous erections and increased arousal that bore no relation to the tanning effect under investigation. That observation triggered a focused effort to understand what was happening at the receptor level — and eventually led to the development of PT-141 as a selective compound aimed at the sexual function application rather than pigmentation.
Chemically, PT-141 is a cyclic lactam analog of the alpha-MSH sequence, with the cyclic structure conferring metabolic stability that the linear parent peptide lacks. Its molecular formula is C50H68N14O10, and its molecular weight sits at approximately 1025 daltons. The compound has high affinity for melanocortin receptor subtypes MC3R and MC4R, with MC4R activation in the hypothalamus considered the primary driver of its pro-sexual effects.
The regulatory history of PT-141 is worth noting because it provides unusual context for a research peptide. In June 2019, the U.S. Food and Drug Administration approved bremelanotide under the brand name Vyleesi as a subcutaneous injection specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval — following two pivotal Phase 3 clinical trials — makes PT-141 one of the very few peptides to have completed the full regulatory pathway from discovery through Phase 3 and into clinical practice. The approved formulation delivers 1.75 mg subcutaneously approximately 45 minutes before anticipated sexual activity, with a limit of one dose per 24 hours.
For researchers and clinicians, the existence of FDA-approved human safety and efficacy data provides a substantially more robust evidence base than is typical for compounds in this category. The peptide continues to be the subject of ongoing research into male sexual dysfunction, additional female sexual dysfunction subtypes, and the broader neuroscience of desire and arousal pathways.
The melanocortin system is a family of G protein-coupled receptors that respond to endogenous peptide ligands derived from proopiomelanocortin (POMC), including alpha-MSH and ACTH. Five receptor subtypes exist (MC1R through MC5R), distributed across diverse tissues and involved in processes ranging from pigmentation to energy homeostasis to inflammation. PT-141’s pro-sexual effects are primarily attributed to its agonism at MC4R, which is densely expressed in the paraventricular nucleus (PVN) of the hypothalamus — a region that serves as a critical integration hub for autonomic, endocrine, and behavioral sexual responses.
When PT-141 binds and activates MC4R in the PVN, it triggers a downstream cascade that includes activation of oxytocin-containing neurons projecting to the spinal cord, as well as indirect modulation of the mesolimbic dopamine system. Electrophysiological studies have shown that MC4R activation increases the firing rate of dopaminergic neurons in the ventral tegmental area (VTA), and the mesolimbic projection from the VTA to the nucleus accumbens is considered the primary neural substrate for motivated behavior and reward anticipation. By engaging this circuit, PT-141 appears to increase the motivational salience of sexual stimuli rather than simply lowering a peripheral resistance to genital response.
The interplay between melanocortin signaling, dopamine, and oxytocin represents the core of PT-141’s mechanism and distinguishes it from all approved sexual function therapies. Research in animal models has shown that intracerebral administration of MC4R agonists induces penile erection through an oxytocin-dependent pathway — blocking oxytocin receptors substantially attenuates the pro-erectile effect. Parallel work has demonstrated that systemic MC4R agonism elevates dopamine release in the nucleus accumbens shell, as measured by in vivo microdialysis, correlating with increased investigatory and copulatory behaviors in rodents.
In humans, the functional consequence of this dual neurochemical activation is an increase in subjective sexual desire and arousal that can occur even in the absence of external sexual stimuli — a feature that distinguishes PT-141’s effect profile from that of PDE5 inhibitors, which require sexual stimulation to be effective. Clinical trial participants described increased “spontaneous” desire — desire not necessarily prompted by a partner’s behavior — which aligns mechanistically with the compound’s action on motivation circuitry rather than solely on peripheral response.
The distinction between central and peripheral mechanisms of action has practical consequences for patient populations and research applications. Vascular-acting agents such as PDE5 inhibitors require intact nitric oxide signaling in penile or clitoral vasculature; their efficacy is therefore substantially reduced in patients with vascular endothelial dysfunction, diabetes-related autonomic neuropathy, or radical pelvic surgery. PT-141’s central mechanism bypasses this vascular requirement, engaging the motivational and autonomic pathways at a level upstream of the peripheral effector mechanisms.
Neuroimaging studies have offered preliminary support for this mechanistic framework. fMRI data from a small human trial showed increased activation in regions including the anterior cingulate cortex and insula following bremelanotide administration — areas associated with interoceptive awareness, emotional salience, and motivated behavior. These patterns are qualitatively distinct from what is observed with vascular-acting agents and consistent with PT-141 engaging the central motivational architecture of sexual desire rather than its peripheral expression.
The RECONNECT program comprised two randomized, double-blind, placebo-controlled Phase 3 trials (BREEZE 1 and BREEZE 2) that together enrolled over 1,200 premenopausal women with HSDD. Participants self-administered bremelanotide 1.75 mg subcutaneously approximately 45 minutes before anticipated sexual activity over a 24-week treatment period, using a prefilled autoinjector. The co-primary endpoints were change from baseline in the Female Sexual Function Index-desire domain (FSFI-desire) score and change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score, which measures distress specifically attributable to low desire.
Both trials met their co-primary endpoints with statistical significance. In the pooled analysis, bremelanotide-treated participants showed approximately 0.5-point greater improvement on the FSFI-desire scale compared to placebo (a clinically meaningful difference given the scale’s range), and approximately 0.3-point greater reduction on the FSDS-DAO item 13 distress score. Responder analyses showed that a significantly higher proportion of women treated with bremelanotide achieved a meaningful within-subject change from baseline compared to placebo. These results supported the FDA’s 2019 approval for HSDD in premenopausal women. Importantly, the trials also provided extensive safety data from over 1,200 women, establishing the adverse event profile with a rigor rarely available for research peptides.
While the FDA approval of bremelanotide is limited to female HSDD, a body of earlier-phase research examined the compound in men with erectile dysfunction (ED). A key proof-of-concept study published in the Journal of Sexual Medicine enrolled men with psychogenic or mild organic ED who had not responded to sildenafil, and found that intranasal bremelanotide (an earlier formulation since discontinued due to blood pressure effects) produced erectile responses in a substantial proportion of subjects at doses below those causing clinically significant hemodynamic changes.
Subsequent work with subcutaneous formulations in men demonstrated dose-dependent increases in erectile function scores, with the signal most robust in men with psychogenic ED and attenuated (though still present) in those with significant organic vascular disease. The mechanistic interpretation is consistent with the central mechanism hypothesis: men whose ED is driven primarily by desire/arousal deficits or psychological factors, rather than vascular endothelial failure, would be expected to show the strongest response to a centrally acting melanocortin agonist. Research into subcutaneous bremelanotide for male ED has continued in investigator-sponsored trials, though no regulatory filing for this indication has been completed as of the current literature.
A substantial preclinical literature, much of it predating the clinical program, established the mechanistic foundation for PT-141’s effects using rodent models. Studies from multiple independent groups demonstrated that central administration of MC4R agonists produced penile erection in male rats through an oxytocin-dependent mechanism — the effect was blocked by oxytocin receptor antagonists and by lesions to the PVN. Female rat studies showed that systemic melanocortin agonists increased lordosis behavior (a measure of sexual receptivity) and reduced the rejection of male approaches, effects interpreted as increases in both receptive and proceptive sexual motivation.
Particularly informative were experiments using MC4R knockout mice, which showed markedly reduced spontaneous sexual behavior and attenuated response to exogenous gonadal hormones, confirming that MC4R signaling is not merely modulatory but integral to normal sexual function. These models also helped establish that the pro-sexual effects of melanocortin agonists are dissociable from their effects on body weight and food intake (mediated by a partly overlapping but distinct circuit), which is relevant for understanding the selectivity of PT-141’s effects in clinical application.
A consistent finding across PT-141 clinical studies is transient increases in blood pressure, typically peaking at approximately 2 hours post-injection and resolving within 12 hours. In the Phase 3 RECONNECT trials, transient increases in systolic blood pressure of greater than 20 mmHg were observed in approximately 13% of bremelanotide-treated women compared to roughly 2% in the placebo group. This finding led to a contraindication for bremelanotide in patients with cardiovascular disease and a recommendation against use with antihypertensive medications. The mechanism underlying the blood pressure effect appears to involve alpha-MSH receptor subtypes on vascular smooth muscle and renal tubular cells, distinct from the hypothalamic MC4R pathway driving the sexual effects — an example of on-target but off-desired-pathway pharmacology that is common in the melanocortin system given the ubiquitous distribution of receptor subtypes.
The most commonly reported adverse event in PT-141 clinical trials is nausea, occurring in approximately 40% of bremelanotide-treated participants versus 1-2% in placebo groups in the Phase 3 trials. Flushing and injection site reactions were also significantly more common than placebo. The nausea is dose-dependent and time-limited, typically resolving within 1-2 hours of administration, and is the primary driver of discontinuation in clinical studies (approximately 8% discontinued due to nausea in the RECONNECT trials). Strategies examined in clinical practice include slower subcutaneous injection technique, prior antiemetic administration, and dose reduction — though the approved 1.75 mg dose in Vyleesi represents the lowest dose demonstrating consistent efficacy in Phase 3. Understanding the dose-tolerability relationship is an active area in ongoing investigator research.
The FDA-approved dose of bremelanotide is 1.75 mg delivered as a single subcutaneous injection via prefilled autoinjector into the abdomen or thigh, administered approximately 45 minutes before anticipated sexual activity. The labeling specifies no more than one dose per 24 hours and advises that if significant nausea occurs, patients should not take the injection for the next anticipated sexual encounter without a mitigation strategy. The approved formulation uses a pH-adjusted aqueous solution delivered via a spring-activated autoinjector designed for self-administration. For reference in research contexts, this 1.75 mg dose serves as a validated human efficacy benchmark with a well-documented safety profile.
Investigational use of PT-141 in research settings has examined a dose range broadly similar to the approved clinical dose but sometimes extending above it. Doses from 0.5 mg to 4.0 mg subcutaneous have appeared in published human research, with the 1.0-1.75 mg range showing the most favorable efficacy-to-tolerability ratio in most studies. Timing of administration has been explored across a range of 30-90 minutes before desired effect onset, with the 45-60 minute window consistently showing optimal results. It is important that any research dosing design account for the transient blood pressure signal observed even at the approved dose; hemodynamic monitoring is appropriate in research settings, particularly at doses exceeding 1.75 mg.
PT-141 for research use is typically supplied as a lyophilized (freeze-dried) powder in sterile vials, requiring reconstitution with bacteriostatic water prior to use. Standard reconstitution practice involves adding bacteriostatic water slowly to the vial and gently swirling (not shaking) to avoid foaming and peptide degradation. Reconstituted PT-141 solution should be stored at 2-8°C and used within 28-30 days of reconstitution; the lyophilized powder, when stored properly at -20°C, maintains stability for substantially longer periods. Because PT-141 is light-sensitive, reconstituted vials should be stored in opaque or amber containers. Our peptide dosing calculator can assist with reconstitution volume calculations for research preparation.
Subcutaneous injection into the abdomen (avoiding the 2-inch radius around the navel) or the outer thigh is the standard route for PT-141, consistent with both the approved clinical formulation and investigational protocols. The injection site should be rotated to minimize local reactions, which are reported in roughly 5-10% of subjects across trials. Intranasal administration was studied in early trials and abandoned after unacceptable blood pressure elevations at doses required for efficacy by this route; the subcutaneous route provides more controlled bioavailability. Intramuscular administration has not been formally studied and is not part of published protocol literature. For questions about specific administration approaches, the AI coach tool can provide general guidance based on published research.
The adverse event profile of PT-141 is well-characterized from Phase 3 clinical data involving over 1,200 women receiving multiple doses across 24 weeks of treatment. Nausea is the most frequently reported adverse effect, occurring in approximately 40% of treated individuals versus 1-2% with placebo. The nausea is typically mild to moderate, peaks around 1-2 hours post-injection, and resolves spontaneously in most cases. Flushing, described as warmth or redness typically involving the face and upper chest, occurs in approximately 20% of treated subjects. Injection site reactions — bruising, pain, tenderness — occur in roughly 5-10%. Headache and fatigue are also reported at higher rates than placebo, though less frequently than nausea or flushing. Transient hyperpigmentation at the injection site has been noted with extended use, consistent with the compound’s activity at melanocortin receptors involved in melanogenesis (MC1R).
The most clinically significant safety signal associated with PT-141 is transient blood pressure elevation. In the RECONNECT trials, transient systolic blood pressure increases of greater than 20 mmHg above baseline occurred in roughly 13% of bremelanotide-treated women, compared to approximately 2% in the placebo group. These increases typically peak at 0.5-2 hours post-injection and resolve within 12 hours. The magnitude of increase is generally modest in healthy subjects but may be clinically significant in those with pre-existing hypertension or cardiovascular disease. The FDA-approved labeling includes a contraindication for patients with known cardiovascular disease and advises against co-administration with antihypertensive medications. Researchers should be aware that heart rate changes are also reported — predominantly mild increases — and that the combination of tachycardia and hypertension, while transient, warrants consideration in any research protocol.
Due to its transient blood pressure-elevating effects, PT-141 is contraindicated in individuals with known cardiovascular disease, uncontrolled hypertension, or a history of stroke. Co-administration with antihypertensive medications may result in paradoxical blood pressure changes or inadequate blood pressure control. There is a clinically significant interaction with naltrexone: PT-141 slows gastric emptying, which can reduce naltrexone absorption and affect steady-state plasma levels of naltrexone and its active metabolite — this is particularly relevant for patients using naltrexone for alcohol use disorder or opioid use disorder. The pharmacokinetic basis for this interaction is PT-141’s mild gastroparesis effect, likely mediated through central mechanisms affecting autonomic tone. Researchers should review complete drug interaction data in the Vyleesi prescribing information and consult the peptide database for updated research literature on specific interaction scenarios.
The core distinction is the level at which each compound acts. Sildenafil (Viagra), tadalafil (Cialis), and related PDE5 inhibitors work in genital tissue by preventing the breakdown of cGMP, thereby maintaining the smooth muscle relaxation and blood vessel dilation required for erection or engorgement. They require sexual stimulation to be effective and have no direct effect on sexual desire or motivation. PT-141, by contrast, acts in the brain — specifically in the hypothalamus — to activate the neural circuits associated with sexual desire and arousal before any peripheral response occurs. For individuals whose primary dysfunction is in the desire or motivation domain rather than the vascular response domain, PT-141’s central mechanism may be more relevant. For those with vascular ED and intact desire, PDE5 inhibitors may be more appropriate. The mechanisms are complementary enough that some research has explored combination use.
Clinical trial participants and individuals using the FDA-approved Vyleesi formulation describe the subjective experience as an increase in sexual desire and mental arousal — a shift in how much sex feels relevant and motivating — rather than a purely physical sensation. Some describe it as a lowering of the “mental barrier” to sexual engagement. The onset is gradual over 45-90 minutes post-injection. Accompanying sensations often include warmth or flushing, and some individuals note a mild sensation of energy or alertness. Nausea may co-occur in approximately 40% of users and can partially offset the desired effect. The experience does not include the sudden, sustained physiological responses associated with stimulant drugs; the effect is more contextual and requires some degree of sexual stimulus to fully manifest.
The current FDA approval of bremelanotide (Vyleesi) is specifically for hypoactive sexual desire disorder in premenopausal women. This narrow approval reflects the indication studied in the Phase 3 program, not a finding that the compound is ineffective or unsafe in men. Early-phase research has examined PT-141 in men with erectile dysfunction, with positive results in some subpopulations, but no company has completed a Phase 3 program in men sufficient to support an NDA for a male indication. The compound’s mechanism — acting on hypothalamic MC4R pathways that are present in both sexes — does not predict sex-specificity of effect, and preclinical research found pro-sexual effects in both male and female animals.
Sexual dysfunction is among the most common and distressing side effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), affecting an estimated 30-70% of individuals taking these medications. SSRI-induced sexual dysfunction often manifests as reduced desire, delayed orgasm, or anorgasmia and is mechanistically distinct from primary HSDD. No Phase 3 trials have specifically enrolled subjects with SSRI-induced sexual dysfunction, and the Vyleesi approval is for primary HSDD in premenopausal women. However, the central dopaminergic mechanism of PT-141 is theoretically plausible as a partial corrective for serotonin-driven suppression of dopamine in the mesolimbic system, and this application has been discussed in the pharmacological literature. Clinician judgment and case-by-case assessment are required; this is not an approved or formally studied indication.
Pharmacokinetic studies of bremelanotide show a time to peak plasma concentration (Tmax) of approximately 1 hour following subcutaneous injection. The terminal elimination half-life is approximately 2.7 hours, meaning plasma levels decline to roughly 50% of peak by about 3-4 hours post-injection. Despite this relatively short half-life, clinical effects on desire and arousal are reported to persist for 6-12 hours in many subjects, suggesting that receptor activation by the peptide sets off a sustained neurochemical response that outlasts circulating peptide levels — consistent with G protein-coupled receptor signaling dynamics and downstream second-messenger cascades that continue after receptor occupancy ends.
In clinical trials with both male and female participants, prolonged or painful erection (priapism) has not been identified as a significant adverse event, distinguishing PT-141’s profile from that of some intracavernosal injection therapies. In the male ED studies, erectile responses were described as physiological in character — achieving and maintaining erection in response to stimulation — rather than the sustained unsolicited erection associated with priapism. The centrally-mediated mechanism is thought to produce a more regulated physiological erectile response compared to direct intracavernosal vasoactive agents. However, anyone experiencing an erection lasting more than 4 hours should seek immediate medical attention regardless of causative agent.
No dedicated drug-alcohol interaction study for bremelanotide has been published, and the Vyleesi prescribing information does not provide specific guidance on alcohol use. From a general pharmacological standpoint, both alcohol and PT-141 have effects on the cardiovascular system (alcohol is vasodilatory; PT-141 can cause transient blood pressure increases), and the combination could produce unpredictable hemodynamic changes. Alcohol’s well-documented suppression of sexual arousal and performance through central sedative mechanisms could also confound or attenuate PT-141’s centrally-mediated desire effects. In the absence of direct study data, caution regarding concurrent alcohol use is clinically prudent, particularly in individuals with cardiovascular risk factors.
Research into PT-141 combinations — particularly with growth hormone secretagogues, oxytocin, or other compounds affecting the hypothalamic-pituitary axis — is limited to preliminary preclinical and case series data. The Peptides Helper database catalogs published research for individual and combination peptide regimens, and the AI coach can help interpret published combination research in context. Given the blood pressure effects associated with PT-141, any combination protocol should be approached with careful attention to cardiovascular safety signals.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.